Henry Leonidas Gomez

List of Publications by Year
in descending order

89 papers	13,066 citations	53794 45 h-index	45317 90 g-index
91 all docs	91 docs citations	91 times ranked	16345 citing authors

#	Article	IF	Citations
1	Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, The, 2012, 379, 633-640.	13.7	1,165
2	Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptorâ€“Positive Metastatic Breast Cancer. Journal of Clinical Oncology, 2009, 27, 5538-5546.	1.6	948
3	Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4236-4244.	1.6	621
4	Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. New England Journal of Medicine, 2014, 371, 107-118.	27.0	621
5	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet, The, 2009, 374, 1512-1520.	13.7	588
6	A Genomic Predictor of Response and Survival Following Taxane-Anthracycline Chemotherapy for Invasive Breast Cancer. JAMA - Journal of the American Medical Association, 2011, 305, 1873.	7.4	531
7	Emergence of Constitutively Active Estrogen Receptor-Î± Mutations in Pretreated Advanced Estrogen Receptorâ€“Positive Breast Cancer. Clinical Cancer Research, 2014, 20, 1757-1767.	7.0	529
8	A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. Journal of Translational Medicine, 2011, 9, 204.	4.4	500
9	Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. Journal of Clinical Oncology, 2007, 25, 5210-5217.	1.6	465
10	Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. New England Journal of Medicine, 2015, 372, 923-932.	27.0	452
11	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clinical Cancer Research, 2016, 22, 1499-1509.	7.0	428
12	Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. Cancer Discovery, 2014, 4, 232-245.	9.4	413
13	Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer. Journal of Clinical Oncology, 2008, 26, 5544-5552.	1.6	407
14	Planning cancer control in Latin America and the Caribbean. Lancet Oncology, The, 2013, 14, 391-436.	10.7	394
15	Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology, 2008, 26, 2999-3005.	1.6	321
16	Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. Journal of Clinical Oncology, 2016, 34, 1034-1042.	1.6	315
17	BIM Expression in Treatment-NaÃ¯ve Cancers Predicts Responsiveness to Kinase Inhibitors. Cancer Discovery, 2011, 1, 352-365.	9.4	268
18	PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Research, 2014, 16, 406.	5.0	267

#	Article	IF	Citations
19	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nature Medicine, 2012, 18, 1052-1059.	30.7	219
20	First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. Journal of Clinical Oncology, 2011, 29, 2766-2772.	1.6	190
21	Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer. Clinical Cancer Research, 2010, 16, 5351-5361.	7.0	185
22	Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncology, The, 2007, 8, 203-211.	10.7	175
23	Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Early Breast Cancer: TEXT and SOFT Trials. Journal of Clinical Oncology, 2016, 34, 2221-2231.	1.6	148
24	The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer and Metastasis Reviews, 2010, 29, 751-759.	5.9	146
25	Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2â€“Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor. Clinical Cancer Research, 2010, 16, 2688-2695.	7.0	137
26	Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2â€“Overexpressing Metastatic Breast Cancer. Journal of Clinical Oncology, 2013, 31, 1947-1953.	1.6	128
27	Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer. Cancer Research, 2013, 73, 6346-6358.	0.9	124
28	Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital Database. Clinical Breast Cancer, 2010, 10, 294-300.	2.4	119
29	Lactate Dehydrogenase B: A Metabolic Marker of Response to Neoadjuvant Chemotherapy in Breast Cancer. Clinical Cancer Research, 2013, 19, 3703-3713.	7.0	119
30	RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy. JAMA Oncology, 2017, 3, 227.	7.1	118
31	Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncology, The, 2012, 13, 696-706.	10.7	109
32	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clinical Cancer Research, 2017, 23, 649-657.	7.0	108
33	Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Research and Treatment, 2012, 134, 333-343.	2.5	106
34	Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Science Translational Medicine, 2016, 8, 334ra53.	12.4	105
35	Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer. Scientific Reports, 2018, 8, 4899.	3.3	91
36	Breast Cancer in Young Women in Latin America: An Unmet, Growing Burden. Oncologist, 2013, 18, 1298-1306.	3.7	84

#	Article	IF	Citations
37	Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Research and Treatment, 2009, 114, 485-493.	2.5	78
38	Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Research and Treatment, 2010, 122, 409-418.	2.5	65
39	Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptorâ€“Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00. Journal of Clinical Oncology, 2016, 34, 3400-3408.	1.6	65
40	In silico evaluation of DNA Damage Inducible Transcript 4 gene (DDIT4) as prognostic biomarker in several malignancies. Scientific Reports, 2017, 7, 1526.	3.3	60
41	A Phase II Trial of Pemetrexed in Advanced Breast Cancer: Clinical Response and Association with Molecular Target Expression. Clinical Cancer Research, 2006, 12, 832-838.	7.0	59
42	A randomized phase II study of lapatinibÂ+Âpazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Research and Treatment, 2013, 137, 471-482.	2.5	55
43	Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3â€98. Psycho-Oncology, 2014, 23, 173-182.	2.3	55
44	Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. Haematologica, 2013, 98, 357-363.	3.5	51
45	A prognostic signature based on three-genes expression in triple-negative breast tumours with residual disease. Npj Genomic Medicine, 2016, 1, 15015.	3.8	50
46	PIK3CA-activating mutations and chemotherapy sensitivity in stage IIâ€“III breast cancer. Breast Cancer Research, 2008, 10, R27.	5.0	49
47	Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America. Clinical and Translational Oncology, 2017, 19, 1478-1488.	2.4	46
48	Treatment of Advanced Hormone-Sensitive Breast Cancer in Postmenopausal Women With Exemestane Alone or in Combination With Celecoxib. Journal of Clinical Oncology, 2008, 26, 1253-1259.	1.6	44
49	A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Research and Treatment, 2013, 137, 755-766.	2.5	42
50	Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy. World Journal of Clinical Oncology, 2016, 7, 387.	2.3	42
51	A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. Breast Cancer Research and Treatment, 2012, 133, 1049-1056.	2.5	39
52	Loss of Heterozygosity at the CYP2D6 Locus in Breast Cancer: Implications for Germline Pharmacogenetic Studies. Journal of the National Cancer Institute, 2015, 107, .	6.3	37
53	Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer. Anti-Cancer Drugs, 2012, 23, 335-341.	1.4	36
54	A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial. Trials, 2013, 14, 228.	1.6	34

#	Article	IF	Citations
55	Breast Cancer in Young Women in Latin America: An Unmet, Growing Burden. Oncologist, 2013, 18, 26-34.	3.7	33
56	Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women. Cancer Research, 2020, 80, 1893-1901.	0.9	29
57	Repeated observation of immune gene sets enrichment in women with non-small cell lung cancer. Oncotarget, 2016, 7, 20282-20292.	1.8	28
58	Advanced Extramammary Paget's Disease of the Groin, Penis, and Scrotum. Clinical Medicine Insights: Oncology, 2014, 8, CMO.S13107.	1.3	27
59	Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Breast Cancer Research and Treatment, 2016, 156, 507-515.	2.5	27
60	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. Journal of the National Cancer Institute, 2016, 108, djw037.	6.3	24
61	Clinicopathological predictors of long-term benefit in breast cancer treated with neoadjuvant chemotherapy. World Journal of Clinical Oncology, 2018, 9, 33-41.	2.3	23
62	Pazopanib: an antiangiogenic drug in perspective. Future Oncology, 2009, 5, 1335-1348.	2.4	22
63	Small-Cell Cancer of the Breast: What Is the Optimal Treatment? A Report and Review of Outcomes. Clinical Breast Cancer, 2012, 12, 287-292.	2.4	22
64	Implication of miRNA in the diagnosis and treatment of breast cancer. Expert Review of Anticancer Therapy, 2011, 11, 1265-1275.	2.4	20
65	A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American) Tj ETQq1 1 0.784314 rgBT /Ov	2.4	20
66	Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma. Clinical and Translational Oncology, 2019, 21, 1127-1134.	2.4	20
67	The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies. British Journal of Haematology, 2002, 118, 218-228.	2.5	19
68	PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Hematology/ Oncology and Stem Cell Therapy, 2014, 7, 142-148.	0.9	18
69	Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies. Biomarkers in Medicine, 2019, 13, 1481-1491.	1.4	16
70	Behaviour of breast cancer molecular subtypes through tumour progression. Clinical and Translational Oncology, 2012, 14, 481-485.	2.4	15
71	Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer. Clinical Breast Cancer, 2021, 21, 239-246.e4.	2.4	15
72	A Phase II Study of Neoadjuvant Gemcitabine Plus Doxorubicin in Stage IIIB Breast Cancer: A Preliminary Report. Seminars in Oncology, 2001, 28, 57-61.	2.2	13

#	Article	IF	Citations
73	Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Current Medical Research and Opinion, 2010, 26, 767-775.	1.9	13
74	Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays. Journal of Surgical Oncology, 2017, 115, 647-662.	1.7	13
75	Triple-negative breast cancer in Peru: 2000 patients and 15 years of experience. PLoS ONE, 2020, 15, e0237811.	2.5	12
76	Ifosfamide plus Cisplatin as Primary Chemotherapy of Advanced Ovarian Cancer. Gynecologic Oncology, 1997, 67, 168-171.	1.4	11
77	Maintenance of Clinical Efficacy After Dose Reduction of Ixabepilone Plus Capecitabine in Patients With Anthracycline- and Taxane-Resistant Metastatic Breast Cancer: A Retrospective Analysis of Pooled Data From 2 Phase III Randomized Clinical Trials. Clinical Breast Cancer, 2012, 12, 240-246.	2.4	11
78	Combined lapatinib and paclitaxel in HER2-positive breast cancer. Nature Reviews Clinical Oncology, 2009, 6, 308-309.	27.6	10
79	Topoisomerase II-Î± as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer. Breast, 2011, 20, 39-45.	2.2	9
80	Prognostic factors for patients with newly diagnosed brain metastasis from breast cancer. CNS Oncology, 2015, 4, 137-145.	3.0	8
81	Breast cancer subtype and survival among Indigenous American women in Peru. PLoS ONE, 2018, 13, e0201287.	2.5	8
82	Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America. Ecancermedicalscience, 2019, 13, 896.	1.1	8
83	Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. Journal of Geriatric Oncology, 2013, 4, 346-352.	1.0	7
84	Global experience with ixabepilone in breast cancer. Expert Review of Anticancer Therapy, 2011, 11, 683-692.	2.4	3
85	Role of undifferentiation markers and androgen receptor expression in tripleâ€negative breast cancer. Breast Journal, 2019, 25, 1316-1319.	1.0	3
86	Prolonged Disease Control in a Patient With Anthracycline- and Taxane-Resistant Breast Cancer. Clinical Breast Cancer, 2009, 9, E1-E3.	2.4	1
87	Addition of amifostine to the CHOP regimen in elderly patients with aggressive non-Hodgkin lymphoma: a phase II trial showing reduction in toxicity without altering long-term survival. Hematology/ Oncology and Stem Cell Therapy, 2012, 5, 152-157.	0.9	1
88	Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy. Obstetrical and Gynecological Survey, 2015, 70, 392-393.	0.4	1
89	PIK3CA mutated, hormonal receptors and HER2: individual targets but partnered in the escape to targeted therapy in breast cancer. Translational Cancer Research, 2016, 5, S789-S793.	1.0	0